Tissue Engineered Cartilage to Repairing Articular Cartilage Defects
Clinical Study of Cartilage Constructed by Autologous Bone Marrow Mesenchymal Stem Cells in Repairing Articular Cartilage Defects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wenjie Ren
- Phone Number: 8613937354075
- Email: 13937354075@163.com
Study Locations
-
-
Henan
-
Xinxiang, Henan, China, 453000
- Recruiting
- The First Affiliated Hospital of Xinxiang Medical College
-
Contact:
- Wenjie Ren
- Phone Number: 13937354075
- Email: 13937354075@163.com
-
Contact:
- Wenjie Ren
- Email: 13937354075@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patients' age ranges from 18 to 65 years old, and gender is not restricted;
- The imaging results show that the epiphyseal growth is mature;
- The defects or localized injuries of joint cartilage caused by trauma or other reasons;
- The injured area is the distal weight-bearing surface of the femoral condyle of the knee joint, with no more than 4 lesions, and there is no injury to the cruciate ligaments;
- The patients voluntarily sign and provide a written informed consent form and are willing to closely cooperate with the doctor's strict postoperative rehabilitation program.
Exclusion Criteria:
- The patient is extremely overweight, with a body mass index greater than 35;
- The lower limb alignment is valgus by more than 10° and varus by more than 5°;
- Multiple ligament injuries;
- There are numerous bad habits such as heavy smoking, drug abuse, and excessive alcohol consumption;
- Has undergone open knee joint surgery within the past six months;
- Has severe joint stiffness or fibrosis;
- Has an allergic constitution or a history of allergic reactions to collagen;
- Has mental abnormalities;
- Cannot or is unwilling to undergo rehabilitation training;
- Has primary cardiovascular diseases, lung diseases, endocrine and metabolic disorders, or other serious diseases that affect their daily life, such as tumors or AIDS;
- Pregnant or lactating women, or those planning to conceive during the trial period;
- Other acute or chronic diseases, for which the researchers consider surgery to be inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tissue-engineered cartilage to repair articular cartilage defects
|
Cartilage constructed by autologous bone marrow mesenchymal stem cells
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
KSS score
Time Frame: before the operation, at 3, 6, 12 and 24 months after the operation.
|
subjective knee clinical and functional score (0-100)score.100 is better in function
|
before the operation, at 3, 6, 12 and 24 months after the operation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Koos scores
Time Frame: before the operation, at 3, 6, 12 and 24 months after the operation.
|
subjective knee functional score (0-100)score.100 is better in function
|
before the operation, at 3, 6, 12 and 24 months after the operation.
|
|
Lysholm score
Time Frame: before the operation, at 3, 6, 12 and 24 months after the operation.
|
subjective knee functional score (0-100)score.100 is better in function
|
before the operation, at 3, 6, 12 and 24 months after the operation.
|
|
WOMAC score
Time Frame: before the operation, at 3, 6, 12 and 24 months after the operation.
|
The higher the index, the more severe the osteoarthritis.
It is less than 80 for mild cases, 80 to 120 for moderate cases, and more than 120 for severe cases.
|
before the operation, at 3, 6, 12 and 24 months after the operation.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TECOA-2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.